- Home
- PAXS vs CBLL Comparison
PAXS vs CBLL Comparison
Compare PAXS & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PAXS | CBLL |
|---|---|---|
| Founded | N/A | 2014 |
| Country | United States | United States |
| Employees | N/A | 280 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.0M | 750.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | PAXS | CBLL |
|---|---|---|
| Price | $14.72 | $20.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.20 |
| AVG Volume (30 Days) | 151.3K | ★ 222.1K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $29.57 |
| Revenue Next Year | N/A | $28.44 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.74 | $10.85 |
| 52 Week High | $16.56 | $24.33 |
Technical Indicators
Market Signals| Indicator | PAXS | CBLL |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 59.91 |
| Support Level | $14.30 | $20.39 |
| Resistance Level | $14.84 | $21.80 |
| Average True Range (ATR) | 0.20 | 0.70 |
| MACD | 0.05 | 0.14 |
| Stochastic Oscillator | 69.31 | 77.89 |
Price Performance
Historical ComparisonAbout PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.
About CBLL CeriBell Inc.
CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.